Action INTREXON CORP
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Intrexon Corp Nyse

Actions

US46122T1025

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Precigen, Inc.(NasdaqGS:PGEN) added to Russell 3000 Growth Index
Precigen, Inc.(NasdaqGS:PGEN) added to Russell Microcap Growth Index
Precigen, Inc.(NasdaqGS:PGEN) added to Russell 3000E Growth Index
Precigen, Inc.(NasdaqGS:PGEN) added to Russell 2000 Growth Index
Precigen, Inc.(NasdaqGS:PGEN) added to Russell 2500 Growth Index
Precigen, Inc.(NasdaqGS:PGEN) added to Russell Small Cap Comp Growth Index
Precigen Share Rise After Recurrent Respiratory Papillomatosis Study Shows 51% of Patients Surgery Free
Precigen, Inc. Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More Than Half of Patients Achieved Complete Response
Precigen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Earnings Flash (PGEN) PRECIGEN Reports Q1 Revenue $1.1M, vs. Street Est of $1.5M
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
North American Morning Briefing : Tech in Focus on -2-
Precigen Shares Fall After Downgrade From JPMorgan
Precigen Reports Full Year 2023 Financial Results and Business Updates
Precigen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
North American Morning Briefing : Stock Futures -2-
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action PGEN
  4. Action
  5. Actualités Intrexon Corp
  6. Autres langues